Form 4: Teva Pharmaceutical Director Rosemary Crane Reports Routine Equity Transactions

Teva Pharmaceutical Industries Ltd. Director Rosemary A. Crane reported the vesting of previously granted restricted share units and the acquisition of new units, increasing her direct beneficial ownership of ordinary shares.

Summary

• Rosemary A. Crane, a Director of Teva Pharmaceutical Industries Ltd., reported changes in her beneficial ownership of company securities.
• On June 6, 2025, 9,632 Restricted Share Units (RSUs) that were granted on June 6, 2024, vested and were subsequently converted into 9,632 Ordinary Shares.
• Following this transaction, Ms. Crane's direct beneficial ownership of Teva Ordinary Shares increased to 113,247.
• Additionally, on June 5, 2025, Ms. Crane was granted 14,492 new Restricted Share Units, which are scheduled to vest on June 5, 2026.

Sentiment

Score: 6

Explanation: The document reports routine equity compensation transactions for a director, including the vesting of existing units and the grant of new ones, which is a neutral to slightly positive event as it aligns management interests with shareholders.

Positives

• Director Rosemary A. Crane's direct beneficial ownership of Teva Ordinary Shares increased to 113,247 following the vesting of RSUs, indicating continued alignment with shareholder interests.
• The grant of 14,492 new Restricted Share Units further aligns the director's long-term incentives with the company's performance and shareholder value creation.

Future Outlook

The newly granted 14,492 Restricted Share Units are expected to vest on June 5, 2026, further aligning the director's compensation with future company performance.

Industry Context

Form 4 filings are standard disclosures for publicly traded companies, detailing changes in beneficial ownership by insiders. These routine transactions, often related to equity compensation plans, are common across the pharmaceutical industry and other sectors, reflecting standard corporate governance practices.

Stakeholder Impact

• Shareholders: The transactions represent routine equity compensation, which aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic focus.

Next Steps

• Vesting of 14,492 Restricted Share Units on June 5, 2026.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, SEC Filing, Insider Transaction, Beneficial Ownership, Director, Equity Compensation, Restricted Share Units, RSU, Ordinary Shares